ESMO’s Daily Reporter

Elena Garralda’s post-ESMO Targeted Anticancer Therapy (TAT) Congress column: the use of ctDNA as a surrogate in early clinical drug development – nearing its end point?

The predictability of response criteria remains controversial in drug development. Numerous reviews and meta-analyses continue to question the reliability of…

Elena Garralda’s post-ESMO Congress On target column: Laying the foundations for next-generation precision oncology

In her latest On target column, published by ESMO’s Daily Reporter, VHIO’s Elena Garralda reflects on the myriad research advances presented at last month’s…